-
Associations of socioeconomic status and phenotypic frailty with incident chronic obstructive pulmonary disease: findings from UK Biobank participants. Chest (IF 9.5) Pub Date : 2024-11-15 Zhaolong Feng,Guoxian Li,Qida He,Na Sun,Tongxing Li,Qiang Han,Hanqing Zhao,Ze Ma,Mengtong Sun,Boyan Liu,Yu Wang,Zexin Lou,Siqian Ma,Yujie Shi,Jianing Li,Ziqing Sun,Miao Jiang,Yueping Shen
BACKGROUND The independent, mediation, interaction, and joint effects of socioeconomic status (SES) and phenotypic frailty on the incidence of chronic obstructive pulmonary disease (COPD) are unclear. RESEARCH QUESTION Do SES and frailty increase the risk of COPD independently or jointly ? Is there an interaction between the two factors in incident COPD? Does frailty play a mediating role between SES
-
Clinical accuracy and risk of harm in asthma related content on TikTok. Chest (IF 9.5) Pub Date : 2024-11-09 John K Murray,Emma McNally,Brian D Kent
-
Quantitative Computed Tomography Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest (IF 9.5) Pub Date : 2024-11-09 Stephen M Humphries,Ayodeji Adegunsoye,M Kristen Demoruelle,Michelle Li Wei Kam,Isabelle Amigues,Tami J Bang,Shawn D Teague,David A Lynch,Jonathan H Chung,Mary E Strek,Jeffrey J Swigris,Joshua J Solomon
BACKGROUND Quantitative chest computed tomography (CT) may be a useful predictor of outcome in rheumatoid arthritis-related interstitial lung disease (RA-ILD). RESEARCH QUESTION What is the utility of deep learning-based lung fibrosis quantitation on CT in assessing disease severity, predicting mortality and identifying progression in RA-ILD? STUDY DESIGN AND METHODS CT scans on a primary cohort of
-
Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Cognitive Impairment. Chest (IF 9.5) Pub Date : 2024-11-09 Hans P A Van Dongen,Eileen B Leary,Christopher Drake,Richard Bogan,Judith Jaeger,Russell Rosenberg,Caroline Streicher,Herriot Tabuteau
BACKGROUND Obstructive sleep apnea (OSA) causes episodes of fragmented sleep and intermittent hypoxia and leads to excessive daytime sleepiness (EDS). Deficits in cognitive function are a troublesome symptom in patients with OSA and EDS. RESEARCH QUESTION How does solriamfetol affect cognitive function in patients with cognitive impairment associated with OSA and EDS? STUDY DESIGN AND METHODS SHARP
-
Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL). Chest (IF 9.5) Pub Date : 2024-11-09 Marcin Waligóra,Marcin Kurzyna,Tatiana Mularek-Kubzdela,Ilona Skoczylas,Łukasz Chrzanowski,Piotr Błaszczak,Miłosz Jaguszewski,Beata Kuśmierczyk,Katarzyna Ptaszyńska,Grzegorz Grześk,Katarzyna Mizia-Stec,Ewa Malinowska,Małgorzata Peregud-Pogorzelska,Ewa Lewicka,Michał Tomaszewski,Wojciech Jacheć,Michał Florczyk,Ewa Mroczek,Zbigniew Gąsior,Agnieszka Pawlak,Katarzyna Betkier-Lipińska,Piotr Pruszczyk,Katarzyna
BACKGROUND The current guidelines do not recommend β-blockers in pulmonary arterial hypertension (PAH) unless indicated by comorbidities. However, the evidence regarding the role of β-blockers in PAH is contradictory. RESEARCH QUESTION What are the effects of β-blockers on clinical outcomes in patients newly diagnosed with pulmonary arterial hypertension (PAH), and how do these outcomes differ based
-
Comparison of clinically meaningful improvements following center-based and home-based tele rehabilitation in people with COPD. Chest (IF 9.5) Pub Date : 2024-11-08 Dr Narelle S Cox,Dr Christine McDonald,Dr Angela T Burge,Dr Catherine J Hill,Ms Janet Bondarenko,Prof Anne E Holland
BACKGROUND Response to pulmonary rehabilitation is not equal for all participants, and may vary across health outcomes for any one individual. Alternative modes of pulmonary rehabilitation delivery, e.g. telerehabilitation, may improve program access but could also affect response to rehabilitation. RESEARCH QUESTIONS What is the rate of clinical response to home-based telerehabilitation compared to
-
Sarcoidosis Treatment Patterns in the United States: 2016-2022. Chest (IF 9.5) Pub Date : 2024-11-08 Ruchika Sangani,Nicholas A Bosch,Praveen Govender,Brittany Scarpato,Allan J Walkey,Julia Newman,Anica C Law,Kari R Gillmeyer,Divya A Shankar
BACKGROUND There are limited FDA-approved medications and real-world data on sarcoidosis treatment in the U.S. and concordance of practice patterns with guideline recommendations have not been well characterized. RESEARCH QUESTION What are the practice patterns and factors associated with treatment for patients with sarcoidosis in the year following diagnosis? STUDY DESIGN AND METHODS We conducted
-
Lessons learned: Risk factors and clinical impact of severe pneumothorax after endoscopic lung volume reduction with endobronchial valves. Chest (IF 9.5) Pub Date : 2024-11-07 Judith Maria Brock,Susanne Annemarie Dittrich,Florian Eichhorn,Kai Schlamp,Konstantina Kontogianni,Felix Jf Herth
BACKGROUND Pneumothorax is a major complication following endoscopic lung volume reduction with valves with a prevalence of up to 34%. While some patients benefit from valve implantation despite pneumothorax, others are significantly impaired after lung collapse. RESEARCH QUESTION What are the differences in the severity grades of pneumothorax and how does that affect our clinical practice? STUDY DESIGN
-
Trends in All-cause Mortality among U.S. Veterans with Sarcoidosis, 2004-2022. Chest (IF 9.5) Pub Date : 2024-11-07 Mohamed I Seedahmed,Mohamed T Albirair,Aaron D Baugh,Walid F Gellad,S Mehdi Nouraie,Kevin F Gibson,Mary A Whooley,Charles E McCulloch,Laura L Koth,Mehrdad Arjomandi
BACKGROUND Sarcoidosis is an idiopathic multiorgan disease with variable clinical outcomes. Comprehensive analysis of sarcoidosis mortality in U.S. Veterans is lacking. RESEARCH QUESTIONS What are the trends in all-cause mortality among U.S. Veterans with sarcoidosis, and how are these trends influenced by demographics, Black vs. White racial disparities, and geographic variability in relation to mortality
-
The dawn of precision medicine in fibrotic interstitial lung disease. Chest (IF 9.5) Pub Date : 2024-11-07 Theodoros Karampitsakos,Bochra Tourki,Jose D Herazo-Maya
TOPIC IMPORTANCE Interstitial lung diseases (ILDs) represent a broad group of heterogeneous parenchymal lung diseases. Some ILDs progress, causing architectural distortion and pulmonary fibrosis, thus are called fibrotic ILDs. Recent studies have shown a beneficial effect of antifibrotic therapy in fibrotic ILDs other than Idiopathic Pulmonary Fibrosis (IPF) that manifest progressive pulmonary fibrosis
-
Parasitic Infections in Pulmonary and Intensive Care Unit Patients: Presentation, Diagnosis, and Treatment. Chest (IF 9.5) Pub Date : 2024-11-07 Adam C Kley,A Clinton White
Parasitic infections in the United States are mostly seen in immigrants and travelers. In many cases, pulmonary and intensive care physicians fail to consider parasitic disease, which can result in delayed diagnosis and adverse outcomes. Almost 2,000 cases of imported malaria are diagnosed in the United States each year. Severe cases can be confused with bacterial sepsis (shock, lactic acidosis, pneumonia
-
Implementation and effectiveness of guideline-recommended clinical activities for children with asthma: population-based cohort. Chest (IF 9.5) Pub Date : 2024-11-06 Z Khalaf,S Saglani,C I Bloom
BACKGROUND Guidelines advise minimising asthma exacerbation risk is achieved partially through good clinical practice activities, including scheduled asthma reviews, inhaler technique checks and asthma management plans. We assessed how frequently these activities are provided and how effective they are in clinical practice. RESEARCH QUESTION Do guidelines-recommended activities such as asthma reviews
-
Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-based Analysis. Chest (IF 9.5) Pub Date : 2024-11-05 Hironao Hozumi,Yoshinari Endo,Masato Kono,Hirotsugu Hasegawa,Koichi Miyashita,Hyogo Naoi,Yuya Aono,Yoichiro Aoshima,Yusuke Inoue,Kazutaka Mori,Hideki Yasui,Yuzo Suzuki,Masato Karayama,Kazuki Furuhashi,Noriyuki Enomoto,Tomoyuki Fujisawa,Naoki Inui,Koshi Yokomura,Takafumi Suda
BACKGROUND Patients with idiopathic pulmonary fibrosis (IPF) may suffer from insomnia and use hypnotics. However, the effect of the use of hypnotics on their clinical course remains unclear. RESEARCH QUESTION Is the use of hypnotics associated with an increased risk of mortality in patients with IPF? STUDY DESIGN AND PARTICIPANTS This study included 99 and 123 patients with IPF from the Hamamatsu and
-
Prophylactic Minocycline for Delirium With Unexpected Death Benefits: What Was Treated Unexpectedly? Chest (IF 9.5) Pub Date : 2024-11-01 Sheng-Yuan Wang,James Cheng-Chung Wei
-
Improving Diagnosis and Management of Pulmonary Hypertension in Interstitial Lung Disease. Chest (IF 9.5) Pub Date : 2024-11-01 Lu Hao,Jisu Xue
-
Current Brain Death Clinical Criteria Are Adequate When Strictly Applied. Chest (IF 9.5) Pub Date : 2024-11-01 Michael DePietro
-
Enhancing Future Research and Clarifying the Role of Minocycline in Refining Delirium Prevention in Critical Care. Chest (IF 9.5) Pub Date : 2024-11-01 Shengshan Xu,Zhuming Lu
-
Are Lung Ultrasound B-Lines Better Than Pulmonary Function Tests in Predicting the Prognosis of Patients With Systemic Sclerosis? Chest (IF 9.5) Pub Date : 2024-11-01 Cetin Yakisik,Damla Azakli,Celal Satici
-
Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease: Comment. Chest (IF 9.5) Pub Date : 2024-11-01 Hineptch Daungsupawong,Viroj Wiwanitkit
-
Reflections on the Recent Study on Minocycline for Delirium Prevention in Patients in the ICU. Chest (IF 9.5) Pub Date : 2024-11-01 Xiaozhen Zhao,Caifeng Li
-
Acute Pulmonary Edema Disguised as Pneumonia. Chest (IF 9.5) Pub Date : 2024-11-01 Ali Naqvi,Mahmoud Abdallah,Ariel L Shiloh
-
A 52-Year-Old Woman With Persistent Back Pain and Multiple Pulmonary Nodules. Chest (IF 9.5) Pub Date : 2024-11-01 Moyan Sun,Abijha Boban,Schaza Rana,Hossny Alaws,Hisham F Qutob
A 52-year-old woman with a history of leiomyoma uteri and tobacco-use disorder in remission presented with 2 months of progressive back pain. Her pain was located between her shoulder blades and was described as constant with intermittent sharp, stabbing sensation. It was nonradiating and aggravated by inspiration. She denied fever, cough, shortness of breath, chest pain, or recent changes in weight
-
A 72-Year-Old Man With Innumerable Bilateral Pulmonary Nodules After Lung Transplantation. Chest (IF 9.5) Pub Date : 2024-11-01 Marwan Mashina,Amir M Emtiazjoo,Mindaugus Rackauskas,Cynthia Gries,Victoria Reams,Joanna M Chaffin,William Weir,Biplab K Saha
A 72-year-old man who underwent bilateral orthotropic lung transplantation for interstitial lung disease 6 months ago presented to the clinic with a 2-week history of cough, shortness of breath, and mid-back pain. The donor was negative for cytomegalovirus (CMV) and positive for Epstein-Barr virus (EBV), and the recipient was positive for both CMV and EBV. He also reported headaches but denied any
-
A New Dawn for Bronchoscopy for Peripheral Lung Lesions? Chest (IF 9.5) Pub Date : 2024-11-01 Ley T Chan,Christopher M Orton,Pallav L Shah
-
A 53-Year-Old Man With Recurrent Cough, Expectoration, and Fever. Chest (IF 9.5) Pub Date : 2024-11-01 Linfan Su,Feng Luo,Zhenguo Zhai,Teng Han
A 53-year-old man was admitted with complaints of recurrent cough, mucopurulent phlegm, and fever for 10 days. These symptoms started in his youth, and he had experienced three or more acute attacks per year in the past 3 years. Persistent nasal obstruction was noticed. When asked for symptoms, the patient denied heartburn, wheezing, aspiration, night sweats, and weight loss. The patient was married
-
A 54-Year-Old Man With High-Grade Fever, Cough, Dyspnea, and Vesiculobullous Skin Eruptions. Chest (IF 9.5) Pub Date : 2024-11-01 Anna Oppliger,Patrick M Meyer Sauteur,Robert Dahmen,Adrian Schibli,Bertram Feil,Mattia Arrigo,Lars C Huber
A 54-year-old Egyptian man with a 5-day history of worsening cough, high-grade fever, and progressive dyspnea was referred to our hospital. A 3-day course of ceftriaxone provided in an outpatient setting showed no clinical improvement. Medical history was unremarkable, except for bilateral pulmonary embolism diagnosed 3 years earlier. The patient actively smoked and denied the use of alcohol and illicit
-
Infant With Recurrent Infections Found to Have a Duplication of the Respiratory Tract. Chest (IF 9.5) Pub Date : 2024-11-01 Ziyin Shang,Cuiwei Liu,Yingxing Liu,Chun Hong,Chaoxiang Yang,Yuan Si
A 10-month-old boy with a weight of 5 kg demonstrated recurrent respiratory infections after birth, respiratory distress after feeding, and slow weight gain. At the time of presentation, he had been experiencing a cough accompanied by pyrexia for > 20 days. Prenatal ultrasound examinations revealed no abnormalities. He was born at full term via cesarean delivery and weighed 2.9 kg at birth. He was
-
Diffuse Alveolar Hemorrhage Due to Bupropion Inhalation. Chest (IF 9.5) Pub Date : 2024-11-01 Zachary Kuschner,Christina Gearges,Zahra Asghar,Junaid Anwar,Glen Granati
Diffuse alveolar hemorrhage (DAH) is a form of hemoptysis caused by disruption of the alveolar-capillary basement membrane causing alveolar bleeding. Inhalation of cocaine and other sympathomimetic agents are described as one of many pathologic causes. We describe what is to the author's knowledge the first reported case of DAH caused by inhalation of bupropion, a norepinephrine-dopamine reuptake inhibitor
-
Odysseus Strings His Bow: Incorporating the Burden of Lymph Node Metastasis into Lung Cancer Staging. Chest (IF 9.5) Pub Date : 2024-11-01 Osarenren Ogbeide,Raymond U Osarogiagbon
-
Risk Assessment Tools in Pulmonary Arterial Hypertension: Why Can't We Be Friends? Chest (IF 9.5) Pub Date : 2024-11-01 Nicole F Ruopp,Harrison W Farber
-
Redefining Echocardiographic Pulmonary Artery Measurements: Insights Into the Presence of Pulmonary Hypertension. Chest (IF 9.5) Pub Date : 2024-11-01 Dinu V Balanescu,Garvan C Kane
-
Infection vs Inflammation: The Bronchiectasis "Tug Of War". Chest (IF 9.5) Pub Date : 2024-11-01 Sanjay H Chotirmall,Anne B Chang,James D Chalmers
-
P2X3 Receptor Antagonists in Chronic Cough: "De Gustibus Non Disputandum Est" (There Is No Arguing About Tastes). Chest (IF 9.5) Pub Date : 2024-11-01 Ahmad Kantar
-
Lung Microbiome: How to Appreciate and Apply It to Clinical Practice. Chest (IF 9.5) Pub Date : 2024-11-01 Margaret Gleeson,Padraic Ridge,Imran Sulaiman
-
Closing the Loop on Diagnostic Testing in Interstitial Lung Disease. Chest (IF 9.5) Pub Date : 2024-11-01 Daniel C Chambers,John A Mackintosh
-
Nana Korobi, Ya Oki: Deep Sedation and the Peri-COVID ICU. Chest (IF 9.5) Pub Date : 2024-11-01 Chris R Dale
-
Being on Time in Pulmonary Arterial Hypertension: Early Diagnosis in High-Risk Populations. Chest (IF 9.5) Pub Date : 2024-11-01 Katarina Zeder
-
Identifying the Best Method for Performing a Spontaneous Breathing Trial. Chest (IF 9.5) Pub Date : 2024-11-01 Pablo Cardinal-Fernández,Luis Collazo,Julio Villanueva
-
Leadership in Emergency Teams: Time to Look Beyond "The Leader". Chest (IF 9.5) Pub Date : 2024-11-01 Sarah Janssens,Stuart Marshall
-
Metabolomic Insights Into Air Pollution: Unraveling the Respiratory Impact Through the UK Biobank. Chest (IF 9.5) Pub Date : 2024-11-01 Min Hyung Ryu
-
The Burden of Air Pollution Exposure on Chronic Respiratory Disease. Chest (IF 9.5) Pub Date : 2024-11-01 Jesse D Berman,Arianne K Baldomero
-
Identifying abnormal exertional breathlessness in COPD: comparing mMRC and CAT with CPET. Chest (IF 9.5) Pub Date : 2024-10-25 Magnus Ekström,Hayley Lewthwaite,Pei Zhi Li,Jean Bourbeau,Wan C Tan,Dennis Jensen,
BACKGROUND Chronic obstructive pulmonary disease (COPD) management is guided by the respiratory symptom burden, assessed using the modified Medical Research Council (mMRC) scale and/or COPD Assessment Test (CAT). RESEARCH QUESTION What is the ability of mMRC and CAT to detect abnormally high exertional breathlessness on incremental cardiopulmonary cycle exercise testing (CPET) in people with COPD?
-
Passive Expiration from Total Lung Capacity Can Estimate Expiratory Function in Infants: A retrospective study. Chest (IF 9.5) Pub Date : 2024-10-25 Avigdor Hevroni,Yael Simpson Lavy,Laurice Boursheh,Ephraim Bar-Yishay
BACKGROUND Evaluating expiratory airway function in infants is challenging, as the gold standard, the raised-volume rapid thoraco-abdominal compression technique is technically difficult and has a high failure rate. RESEARCH QUESTION Are measurements obtained during passive expiration from total lung capacity correlated with forced expiration measurements obtained by the raised-volume technique in
-
Prophylactic antibiotics in adults with acute brain injury who are invasively ventilated in the Intensive Care Unit: A systematic review and meta-analysis. Chest (IF 9.5) Pub Date : 2024-10-25 Kathryn Hadley-Brown,Laura Hailstone,Roisin Devane,Tak Chan,Anthony Devaux,Joshua S Davis,Naomi Hammond,Qiang Li MBioStat,Edward Litton,John Myburgh,Alexis Poole,Joseph Alvin Santos,Ian Seppelt,Steven Y C Tong,Andrew Udy,Balasubramanian Venkatesh,Paul J Young,Anthony P Delaney
BACKGROUND Lower respiratory tract infections are common in patients receiving invasive mechanical ventilation in an Intensive Care Unit (ICU) after an acute brain injury and may have deleterious consequences. RESEARCH QUESTION In adults with acute brain injury receiving invasive mechanical ventilation in an ICU, is the administration of prophylactic parenteral antibiotics, compared to placebo or usual
-
Patterns and Differences in Lung Cancer Treatment - United States, 2015-2020. Chest (IF 9.5) Pub Date : 2024-10-25 Christine M Kava,David A Siegel,Jin Qin,Susan A Sabatino,Reda Wilson,Manxia Wu
BACKGROUND Treatment for lung cancer can improve prognosis, but 5-year survival remains low at 26%. An examination of treatment using data with higher population coverage, and among a broader number of treatment modalities and individual characteristics, would provide greater insight into differences in lung cancer treatment. RESEARCH QUESTION Among adults diagnosed with lung cancer, how does reported
-
Determinants of mortality in patients with COPD: Physical capacity or physical activity? Chest (IF 9.5) Pub Date : 2024-10-25 Anouk W Vaes,Noriane A Sievi,Christian F Clarenbach,Benjamin Waschki,Henrik Watz,Alex J van 't Hul,Martijn A Spruit
-
An End-of-Life Ethics Consult in the ICU: Who Has the Final Say- The Patient or the Family? Chest (IF 9.5) Pub Date : 2024-10-25 Lindsay R Semler,Ellen M Robinson,M Cornelia Cremens,Fred Romain
A 72-year-old gentleman with metastatic pancreatic cancer was admitted to the ICU with increased oxygen demand and confusion, likely related to pulmonary metastases. In the presence of his son, the healthcare agent, and the team, the patient requested to be do-not-attempt-resuscitation and do-not-intubate (DNR/DNI) before losing decision-making capacity. When the patient's brother and another son heard
-
Clinical Efficacy of Serum Anti-glycopeptidolipid-core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in Bronchiectasis: A European Multicenter Cohort Study. Chest (IF 9.5) Pub Date : 2024-10-25 Hayoung Choi,Chloe Hughes,Zsofia Eke,Morven Shuttleworth,Michal Shteinberg,Eva Polverino,Pieter C Goeminne,Tobias Welte,Francesco Blasi,Amelia Shoemark,Merete B Long,Stefano Aliberti,Charles S Haworth,Felix C Ringshausen,Michael R Loebinger,Natalie Lorent,James D Chalmers
BACKGROUND Serum anti-glycopeptidolipid (GPL) core immunoglobuin A (IgA) antibody test has been proposed as a diagnostic tool for Mycobacterium avium complex pulmonary diseases. Cross-reactivity with other non-tuberculous mycobacteria (NTM), including M. abscessus, indicates that it may have a role as a broader screening test for NTM pulmonary disease (NTM-PD). NTM-PD is believed to be underdiagnosed
-
Single-inhaler triple versus LABA-ICS therapy for COPD: Comparative safety in real-world clinical practice. Chest (IF 9.5) Pub Date : 2024-10-24 Samy Suissa,Sophie Dell'Aniello,Pierre Ernst
BACKGROUND Recent treatment guidelines for chronic obstructive pulmonary disease (COPD) have replaced the long-acting beta2-agonist and inhaled corticosteroid (LABA-ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA-LABA-ICS). Yet, the corresponding trials reported numerically higher incidences of cardiovascular adverse events with triple therapy
-
Aspergillus Serologic Findings and Clinical Outcomes in Patients With Bronchiectasis: Data From the European Bronchiectasis Registry Chest (IF 9.5) Pub Date : 2024-10-24 J. Pollock, P.C. Goeminne, S. Aliberti, E. Polverino, M.L. Crichton, F.C. Ringshausen, R. Dhar, M. Vendrell, P.R. Burgel, C.S. Haworth, A. De Soyza, J. De Gracia, A. Bossios, J. Rademacher, A. Grünewaldt, M. McDonnell, D. Stolz, O. Sibila, M. van der Eerden, P. Kauppi, A.T. Hill, R. Wilson, A. Amorim, O. Munteanu, R. Menendez, A. Torres, T. Welte, F. Blasi, W. Boersma, J.S. Elborn, M. Shteinberg, K
Aspergillus species cause diverse clinical manifestations in bronchiectasis including allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitization (AS), and raised IgG indicating exposure to or infection with Aspergillus.
-
"Creation of an Advanced Practice Respiratory Therapy (APRT) Education Program". Chest (IF 9.5) Pub Date : 2024-10-24 Sarah M Varekojis,Jessica Schweller,Georgianna Sergakis
The Advanced Practice Respiratory Therapist (APRT) is a new healthcare practitioner trained to provide a scope of practice that exceeds that of the registered respiratory therapist (RRT) and is aligned with an advanced practice provider (APP) role. As part of a physician-led team, APRTs are trained to provide diagnostic and therapeutic patient care services in multiple settings across the health care
-
Impact of empirical treatment recommendations from 2017 European guidelines for nosocomial pneumonia. Chest (IF 9.5) Pub Date : 2024-10-24 Davide Calabretta,Catia Cilloniz,Albert Gabarrus,Ana Motos,Flavia Galli,Miquel Ferrer,Laia Fernandez-Barat,Andrea Palomeque,Giovanni Mistraletti,Mauro Panigada,Cristina Pitart,Mateu Espasa,Ignacio Martin-Loeches,Antoni Torres
-
Impact of Exclusive Mouth Route and Lateral Position on the Efficacy of Oronasal CPAP to Treat OSA in Patients With OSA Adapted to Oronasal Mask Chest (IF 9.5) Pub Date : 2024-10-24 Jeane Lima de Andrade Xavier PhD, Mariana Delgado Fernandes MD PhD, Rafaela Garcia Santos de Andrade PhD, Pedro R. Genta MD PhD, Geraldo Lorenzi-Filho MD PhD
Oronasal masks are used widely for treating OSA with CPAP. However, oronasal CPAP is associated with lower effectiveness and lower adherence than nasal CPAP.
-
Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema. Chest (IF 9.5) Pub Date : 2024-10-23 Huajing Yang,Yuqiong Yang,Fengyan Wang,Chengyu Miao,Zizheng Chen,Shanshan Zha,Xueping Li,Jiawei Chen,Aiqi Song,Rongchang Chen,Zhenyu Liang
BACKGROUND The clinical and prognostic characteristics of mild-to-moderate chronic obstructive pulmonary disease (COPD) with and without emphysema remain inadequately investigated. RESEARCH QUESTION Do the clinical and prognostic characteristics differ between mild- to-moderate COPD with and without emphysema? STUDY DESIGN AND METHODS We obtained clinical data of 989 participants with mild-to-moderate
-
Association Between Thrombus Histopathology and Hemodynamic Outcomes Among Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Endarterectomy Chest (IF 9.5) Pub Date : 2024-10-23 Louisa A. Mounsey MD, Daniel Alape Moya MD, Cameron Wright MD, Nathaniel Langer MD, James R. Stone MD PhD, Richard Channick MD, Alexandra K. Wong MD, Josanna Rodriguez-Lopez MD, Alison S. Witkin MD
Pulmonary endarterectomy (PEA) is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH). Although most have normalization of pulmonary artery (PA) pressures, development of residual pulmonary hypertension (RPH) is challenging to predict.
-
A Comparison of GOLD and STAR Severity Stages in Individuals With COPD Undergoing Pulmonary Rehabilitation Chest (IF 9.5) Pub Date : 2024-10-19 Pasquale Ambrosino MD PhD, Michele Vitacca MD FERS, Giuseppina Marcuccio MD PhD, Antonio Spanevello MD FERS, Nicolino Ambrosino MD FERS, Mauro Maniscalco MD PhD FERS
Alongside the recognized Global Initiative for Obstructive Lung Disease (GOLD) classification, the Staging of Airflow Obstruction by Ratio (STAR) severity scheme has been proposed for categorizing COPD.
-
Perspectives of Clinicians on the Value of the Get to Know Me Board in the ICU Chest (IF 9.5) Pub Date : 2024-10-18 Sumera R. Ahmad MBBS, Lori Rhudy RN PhD, Amelia K. Barwise MBBCh PhD, Mahmut C. Ozkan MD, Ognjen Gajic MD, Lioudmila V. Karnatovskaia MD
Critical illness can render patients at heightened risk of anonymity, loss of dignity, and dehumanization. Because dehumanization results in significant patient distress, it is imperative to find ways to humanize care in the ICU. A Get to Know Me board (GTKMB) is a personal patient profile designed to bring the patient from anonymity; however, its widespread adoption has been challenging.
-
A one-year weight management programme for difficult-to-treat asthma with obesity: a randomised controlled study. Chest (IF 9.5) Pub Date : 2024-10-18 Varun Sharma,Helen Clare Ricketts,Louise McCombie,Naomi Brosnahan,Luisa Crawford,Lesley Slaughter,Anna Goodfellow,Femke Steffensen,Rekha Chaudhuri,Michael E J Lean,Douglas C Cowan
BACKGROUND Obesity-associated asthma results in increased morbidity and mortality. We report one-year asthma outcomes with the Counterweight-Plus weight management programme (CWP) compared to usual care (UC) in a single-centre, randomised, controlled trial in patients with difficult-to-treat asthma and obesity. RESEARCH QUESTION Can CWP use result in improved asthma control and quality of life compared
-
Comparative Effectiveness of Albumin vs No Albumin on Renal Replacement Therapy and Mortality in Patients With Septic Shock and Renal Impairment Chest (IF 9.5) Pub Date : 2024-10-18 Asad E. Patanwala PharmD MPH, Alexander H. Flannery PharmD PhD, Hemalkumar B. Mehta PhD, Thomas E. Hills MBChB DPhil, Colin J. McArthur MBChB, Brian L. Erstad PharmD
Albumin infusions may be renally protective or harmful in patients with septic shock who have kidney impairment. This can affect the need for renal replacement therapy (RRT) and in-hospital mortality.
-
Isolation of Genetically Distinct Strains Within the Same Species During Treatment of Mycobacterium Avium Complex Pulmonary Disease Chest (IF 9.5) Pub Date : 2024-10-18 Jiwon Lee MD, Su-Jin Park MSc, Sangmi Kim MSc, Han Na Lee MD, Heungsup Sung MD, Tae Sun Shim MD, Kyung-Wook Jo MD
Research on isolating genetically different strains within the same species in patients undergoing treatment for Mycobacterium avium complex (MAC) pulmonary disease (PD) is limited. We investigated the frequency of genetically distinct strains identified within the same species among on-treatment isolates compared with pretreatment isolates throughout the course of MAC-PD treatment.